Journal of Oncology Pharmacy Practice

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Webster, P. J.
Right arrow Articles by Hamett, P. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Webster, P. J.
Right arrow Articles by Hamett, P. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Oncology Pharmacy Practice, Vol. 1, No. 4, 41-48 (1995)
DOI: 10.1177/107815529500100405

Does determination of tissue platinum levels by mass spectroscopy have potential for monitoring exposure of pharmacy personnel to platinum-based antineoplastic drugs? A pilot study

Penelope Jane Webster, Dip Hosp Pharm

Department of Pharmacy, Westmead Hospital and Community Health Services, Westmead NSW 2145, Australia.

Kingsley Ng, MSc

Departments of Pharmacy and Medical Oncology, Westmead Hospital and Community Health Services, WestmeadDepartment of Biochemistry, Royal Prince Alfred Hospital, Camperdown, Australia

Peter Snitch, BSc Hons

Departments of Pharmacy and Medical Oncology, Westmead Hospital and Community Health Services, WestmeadDepartment of Biochemistry, Royal Prince Alfred Hospital, Camperdown, Australia

Sandra L. Jones, Dip Med Sci

Departments of Pharmacy and Medical Oncology, Westmead Hospital and Community Health Services, WestmeadDepartment of Biochemistry, Royal Prince Alfred Hospital, Camperdown, Australia

Nicola Amos

Paul R. Hamett, PhD

Departments of Pharmacy and Medical Oncology, Westmead Hospital and Community Health Services, WestmeadDepartment of Biochemistry, Royal Prince Alfred Hospital, Camperdown, Australia

The mutagenic and carcinogenic properties of cyto toxic drugs have led to concern over potential haz ards to pharmacy personnel who are required to prepare cytotoxic drugs. The platinum compounds cisplatin and carboplatin are frequently used antican cer agents and are unique by virtue of their suitability for quantification by highly sensitive physical meth ods such as inductively coupled plasma mass spec troscopy (ICPMS). We have performed a pilot study of ICPMS determination of platinum levels in biological samples from pharmacists preparing chemotherapy, including platinum-based antineoplastic drugs. In pa tients treated with platinum compounds, elemental platinum was readily detected in plasma and whole leukocytes and bound to leukocyte DNA for at least 4 weeks after treatment. However, in 28 pharmacists from our institution (18 involved in preparation of platinum-based compounds, 10 controls), tissue plat inum levels were below the limit of detection (0.05 nmol/L) by ICPMS. ICPMS measurement of platinum levels has the potential to be used to monitor health care workers for exposure to platinum-based cytotox ics. Exposure may result from accidental exposure to a platinum-based compound or may be due to poor technique by personnel preparing chemotherapy doses. We are intending to institute a prospective monitoring policy to gather further data.

Key Words: Platinum compounds • mass spectroscopy • occupational exposure.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?